BioSpace News Archive

RespireRx Pharmaceuticals Inc., is pleased to announce that , Mr. Tim Jones and RespireRx have transitioned from the provisional period that commenced on May 6, 2020 to the three year, long-term portion of the employment contract with Mr. Jones as its President and Chief Executive Officer.

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that its president and chief executive officer, Steven Lo, will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 3:00 pm ET.

Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced a collaboration with Hospital for Special Surgery in New York City.

89bio, Inc. announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Monday, August 10, 2020 at 11:30 AM ET and the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020 at 10:00 AM ET.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie.

Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with bevacizumab

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced that it will host a conference call on Monday, August 10, 2020, at 4:30 p.m. ET to discuss its financial results for the three months ended June 30, 2020, and recent operational highlights.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2020.

Net income was $0.16 per basic share and $0.13 per diluted share, compared to $0.41 per basic share and $0.32 per diluted share

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, announced that it plans to release its second quarter 2020 financial results after market close on Monday, August 10, 2020.